LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that, as expected, it received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (the “Staff”) dated November 11, 2008 stating that the company has not regained compliance with Nasdaq Marketplace Rule 4450(b)(1)(A), which requires a listed company to maintain a minimum $50 million market capitalization for continued listing on The Nasdaq Global Market. This notice follows prior correspondence from the Staff regarding the company’s market capitalization, which was disclosed in the company’s press release dated October 14, 2008.
